← Human Trials & Peer-Reviewed Studies
Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study
Plain-language guide to PMID 40329175 (2025): observational study of CGRP (Calcitonin Gene-Related Peptide) in 1088 patients, migraine.
Key Facts
- PMID
- 40329175
- Journal
- The journal of headache and pain
- Year
- 2025
- Study type
- Observational Study
- Authors
- de Tommaso M et al. (5 authors)
- DOI
- 10.1186/s10194-025-02034-y
What This Study Did, in Plain Language
What Was Tested
Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this observational study publication.
Migraine is a common comorbidity with fibromyalgia (FM).
CGRP is a potent inflammatory neuropeptide that may play a role in somatic and visceral pain either inflammatory or neuropathic.
Who Took Part
The abstract describes 1088 patients taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Among 1088 patients came for the first visit to their headache Center between January 1, 2021, and December 31, 2022, the researchers examined six-month outcomes of 148 migraine patients prescribed various monoclonal antibodies to CGRP, erenumab, galcanezumab, and fremanezumab.
One hundred and twenty-two patients were selected, 26 of whom suffered from FM.
How the Study Was Run
In the FM patients, the researchers evaluated the FIQ and the intensity of somatic pain using a numerical rating scale from 0 to 10.
What Was Measured
Topics PubMed links to this paper include Fibromyalgia, Migraine Disorders, Calcitonin Gene-Related Peptide, Cross-Sectional Studies, Antibodies, Monoclonal, Comorbidity and Antibodies, Monoclonal, Humanized.
The authors tagged it with the keywords CGRP, Fibromyalgia disability, Headache features and Monoclonal antibodies.
What This Means in Plain Language
This is an observational study of CGRP (Calcitonin Gene-Related Peptide) in 1088 patients in people with migraine.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (The journal of headache and pain), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.